KAISER FOUNDATION HOSPITALS
975 SERENO DR
Elaine Siegfried, M.D., is professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, St. Louis, Mo. She also is a member of the Dermatology Times Editorial Advisory board and a co-medical editor.
October 04, 2019
The Prior Authorizations process creates inconsistent application, physician dissatisfaction and opportunity for life-threatening adverse events for patients.
July 08, 2019
When it comes to easily-recognized, benign, self-limited conditions like warts and molluscum, Dr. Siegfried calls herself a treatment nihilist. Learn why in this article.
March 26, 2019
Most dermatologists train in a clinical setting that accepts underinsured patients, but only some physicians continue along this path. Elaine Siegfried, M.D. offers her point of view on the pros and cons of working with this population, and discusses how to maintain a socioeconomically inclusive dermatology practice.
October 02, 2018
Developing doctor-patient relationships are key to avoiding oversimplification of characteristics like race and gender, which can result in stereotyping and medical mismanagement.
December 04, 2015
Dermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. In this final segment, the two discuss whether a waiting period is necessary before treating acne scars and the questionable existence of pityrosporum folliculitis.
November 16, 2015
In part three of the discussion on isotretinoin, our experts discuss distinguishing sinus tracts or keratinous cysts from nodular areas of inflammation and techniques for treating via intralesional injection.
October 23, 2015
Dermatology Times editorial advisor, Dr. Elaine Siegfried continues the discussion on isotretinoin with James Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. Here, the two discuss isotretinoin dosing and side effects.
October 15, 2015
Dr. Jim Leyden, an active participant in isotretinoin's drug development process, discusses many of the important initial clinical observations and those that others have made over the years.
September 17, 2015
Dermatology Times editorial advisor Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, aside from being a member of the famed Acne Mafia, was a really active participant in the drug development process for isotretinoin, a drug for which, the institutional memory about that process may be fading. The two discuss many of the important initial clinical observations and those that others have made over the years.
January 15, 2015
Dermatology Times editorial advisor, Elaine Siegfried, M.D., talks with Peter Lio, M.D., assistant professor of clinical dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine, and private practice, Dermatology and Aesthetics of Wicker Park, Wicker Park, Chicago, about his interest in alternative medicine and the legitimacy and usefulness of certain techniques and therapies.
